Rare Disease CROs in Switzerland

Swiss CDMO providing integrated drug substance and drug product development services including API synthesis, process development, and highly potent compound manufacturing.

Swiss independent Phase I and early-phase clinical CRO in Basel with a dedicated 24-bed clinical pharmacology unit, specializing in first-in-human studies for oncology, cardiovascular, and CNS compounds.

European CDMO network with 11 GMP facilities providing integrated API, drug product, and packaging services from pre-clinical through commercial scale including peptides, lipids, and injectables.

LabCorp Drug Development centre in Basel providing central laboratory services, companion diagnostics development, and specialised clinical testing for European pharma sponsors.

Swiss full-service CRO operating in 56 countries with 3,000 staff, specializing in pivotal Phase II-III clinical trials in oncology, hematology, multiple sclerosis, and rare diseases.

Independent pharmaceutical development services company in Basel providing drug formulation development, analytical development, and stability testing for injectable and biopharmaceutical products.